The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
Abstract
Background: Cholinesterase inhibitors with additional nicotinic activity, such as galantamine, may be useful in PD patients with dementia (PDD) since stimulation of nicotinic receptors may prevent the down‐regualation that is likely to accompany cholinesterase inhibition and facilitate dopamine release in the striatum. Methods: Sixteen PDD patients (six female) with onset of cognitive impairment after at least one year with parkinsonism participated in this open‐label trial of galantamine. Cognitive, psychiatric, and motor symptoms were assessed before and after 8 weeks of treatment with galantamine using unstructured clinical assessment as well as rating scales including the Mini‐Mental State Examination (MMSE), clock drawing test, verbal fluency and selected items from the Neuropsychiatric Inventory (NPI). Results: Age (mean, SD) was 75.6 (5.2) years, duration of PD 13.4 (5.9), duration of dementia 2.1 (1.7) years, Hoehn and Yahr score was 3.8 (0.8) and baseline MMSE score was 17.7 (6.7). Side‐effects caused discontinuation in three patients, but were rare and mild in the remaining 13. Improvement of global mental symptoms was noted in eight patients, whereas worsening was reported in four. Hallucinations improved in seven of the nine patients with hallucinations before treatment. Parkinsonism improved in six patients, but a mild worsening of tremor was noted in three. Clock‐drawing improved (p = 0.016), and trends towards improvement on MMSE (p = 0.09) and verbal fluency (p = 0.16) were found. Conclusions: Although controlled trials are needed, the findings suggest that galantamine is useful in patients with PDD. Copyright © 2003 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study
Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb06891.x · Cited by 811
Self-citation
Cited by
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418
Calabresi, P., Picconi, B., Parnetti, L., & Di Filippo, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70600-7 · Cited by 338
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Self-citationDelivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Anxiety rating scales in Parkinson's disease: Critique and recommendations
Leentjens, A. F. G., Dujardin, K., Marsh, L., Martinez‐Martin, P., Richard, I. H., Starkstein, S. E., Weintraub, D., Sampaio, C., Poewe, W., Rascol, O., et al. (2008) · Movement Disorders · doi:10.1002/mds.22233 · Cited by 275
Metadata
- Authors
- Aarsland, D., Hutchinson, M., & Larsen, J. P.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2003-09-11
- Volume
- 18
- Issue
- 10
- Pages
- 937-941
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1998510250
- Cited by
- 219
- References
- 4
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.